Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | TTK | P33981 | 2/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.31 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20875580 | 0.85 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL20875382 | 0.85 | MEN1 (0.33) | MEN1KMT2APIM1TTKPIM2 | |
| SCHEMBL2881822 | 0.80 | MEN1 (0.39) | MEN1KMT2AALDH1A1KDM4EGLA | |
| SCHEMBL22543694 | 0.78 | MERTK (0.34) | ALDH1A1 | |
| SCHEMBL12005721 | 0.77 | MTOR (0.39) | MEN1KMT2APIM1TTKPIM2 | |
| SCHEMBL20875403 | 0.77 | MEN1 (0.36) | MEN1KMT2AALDH1A1KDM4EGLA | |
| SCHEMBL1811493 | 0.77 | ALDH1A1 (0.37) | MEN1KMT2AALDH1A1KDM4EGLA | |
| SCHEMBL23126624 | 0.75 | MEN1 (0.34) | MEN1KMT2AALDH1A1KDM4EMAPT | |
| SCHEMBL25216988 | 0.74 | MEN1 (0.35) | MEN1KMT2AALDH1A1KDM4EGLA | |
| SCHEMBL20875558 | 0.74 | PIM1 (0.36) | MEN1KMT2APIM1TTKPIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023217201-A2 | NOVEL PYRIMIDO-HETEROCYCLIC NOVEL COMPOUND SERVING AS WEE1 INHIBITOR AND APPLICATION THEREOF | 杭州德睿智药科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| WO-2023125944-A1 | COMPOUND CONTAINING HETEROCYCLIC RING | 正大天晴药业集团股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| WO-2023072301-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-111315747-B | Dihydropyrazolopyrimidine compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230118115-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230118115-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | NUVATION BIO INC (US) | 2023-04-06 | — | — | US | disclosed |
| CN-115838375-A | Pyrimido-dihydro-pyrazolone derivative, pharmaceutically acceptable salt thereof, and preparation method and application thereof | 优领医药科技(香港)有限公司 | 2023-03-24 | — | — | CN | disclosed |
| US-11479555-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase | NEWAVE PHARMACEUTICAL INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-07-14 | — | — | US | disclosed |
| EP-2213673-B1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2013-06-05 | — | — | EP | disclosed |
| US-8329711-B2 | Pyridone-substituted-dihydropyrazolopyrimidinone derivative | MSD K.K. (JP) | 2012-12-11 | — | — | US | disclosed |
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | SAGARA TAKESHI | 2011-08-04 | — | — | US | disclosed |
| US-7935708-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20100221211-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD K.K. (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2213673-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-08-04 | — | — | EP | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189130-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | MEN1 2199/4885KMT2A 1433/4885PIM1 607/4885 |
| US-20230118115-A1 | SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINES AS WEE1 INHIBITORS | WEE1, WEE2, DPYD | MEN1 2058/4885KMT2A 1842/4885PIM1 963/4885 |
| US-20230109104-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | MEN1 326/4885KMT2A 2106/4885PIM1 680/4885 |
| US-20100221211-A1 | PYRIDONE-SUBSTITUTED-DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | WEE1, WEE2, CCNE1 | MEN1 528/4885KMT2A 1568/4885PIM1 536/4885 |
| US-20220220115-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | WEE1, WEE2, NME1 | MEN1 326/4885KMT2A 2106/4885PIM1 680/4885 |
| US-11479555-B2 | Substituted 1,2-dihydro-3H-pyrazolo[3,4-D]pyrimidin-3-ones as inhibitors of WEE-1 kinase | WEE1, WEE2, PHKG1 | MEN1 755/4885KMT2A 1134/4885PIM1 505/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | MEN1 2199/4885KMT2A 1433/4885PIM1 607/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | MEN1 2199/4885KMT2A 1433/4885PIM1 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.